Trials / Completed
CompletedNCT00644124
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the selected dose of aflibercept when it is combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin B-cell lymphoma, and to determine how the body handles aflibercept when it is administered with R-CHOP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aflibercept | in combination with standard treatment R-CHOP |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-03-26
- Last updated
- 2016-05-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00644124. Inclusion in this directory is not an endorsement.